Clinical Trial: Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
Study Status: Completed
Recruit Status: RECRUITING
Condition: Immunosuppression
Study Type: INTERVENTIONAL
Official Title: Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
Brief Summary:
To determine whether providing a recombinant booster COVID-19 vaccine improves sustained humoral and cell-mediated immunogenicity against SARS-CoV-2 in immunosuppressed patients with Inflammatory Bowel Disease (IBD) and/or solid organ transplant recipients.120 participants will be enrolled and can expect to be on study for 6 months.
Read more